Marc-André Gagnon, PhD
Carleton University
Pharmaceutical Policies
613-520-2600 ext. 1690 | [email protected] | @MAG_Rx
(Available for interviews in French/English)
Marc-Andre Gagnon is an expert in political economy and health policy. He is an Associate Professor at the School of Public Policy and Administration at Carleton University. He is also a Research Fellow with the Pharmaceutical Policy Research Collaboration and with the Edmond J. Safra Centre for Ethics at Harvard University for a Lab Project on Institutional Corruption. His current research focuses on Drug pricing, Pharmacare, Innovation Policy, Pharmaceutical Promotion and the corruption of medical research. Marc-Andre holds a PhD in Political Science from York University and a Masters of Advanced Study in Economics from Paris-1 Sorbonne and Ecole Normale Superieure de Fontenay/St-Cloud.
Download a hi-res photo of Marc-André Gagnon
Commentaries by Marc-André Gagnon:
Free medicines for rich kids is actually a fair and efficient policy
Quebec’s outdated drug coverage policies should not be a model for the rest of Canada
Comment baisser le coût des médicaments au Québec?
Why employers in Canada waste $5 billion a year on inefficient drug coverage // L’inefficacité de l’assurance-médicaments privée coûte 5 milliards chaque année aux entreprises
How a national drug plan can boost the Canadian economy // Comment un régime d’assurance-médicaments national relancerait l’économie canadienne
Who’s afraid of universal pharmacare?
Beware the ghosts of medical research // Gare aux fantômes qui hantent la recherche médicale
How Canada artificially inflates the cost of prescription drugs to the tune of $2-billion // Médicaments: Un gaspillage annuel de deux milliards
Our drug plan; costly, inefficient and inequitable
Provinces must stand together on drug purchases
Quelle stratégie québécoise pour l’accès au médicament?
Patent protection for brand name drugs should come at a price // Il devrait y avoir un prix à payer pour la protection par brevet des médicaments d’origine
Let’s look at the evidence around the pharmacare debate – Reply to Yanick Labrie from the Montreal Economic Institute
Podcasts with Marc-André Gagnon:
Audio Podcast: L’inefficacité de l’assurance-médicaments privée coûte 5 milliards de dollars chaque année aux entreprises
Audio Podast: Why Canadian researchers need to be more vocal in the media
Conférence : les défis de l’interdépendance entre chercheurs et journalistes
Posters by Marc-André Gagnon:
“When it comes to prescription drugs, Canada’s current system is plagued by massive waste, massive costs and too many people unable to afford their medicine.”
Read the commentary: Who’s afraid of universal pharmacare?
“Lorsqu’on en vient aux médicaments d’ordonnance, le systéme Canadien se caractéise par son immense gaspillage, ses coûts excessifs, et trop de gens incapables d’accéder aux médicaments dont ils ont besoin.”
Lisez l’article (en anglais): Who’s afraid of universal pharmacare?
“Le gaspillage induit par les régimes privés d’assurance-médicaments coûte plus de $5 milliards par année aux entreprises canadiennes.”
Lisez l’article: L’inefficacité de l’assurance-médicaments privée coûte 5 milliards de dollars chaque année aux entreprises
“My role as a researchers is not only to bring forth evidence, but also to raise my voice when political decisions are not evidence-based.”
Read the commentary : Canadian researchers call on fellow scientists to be more vocal in the media
“Mon rôle en tant que chercheur est non seulement de rapporter les faits, mais aussi d’élever la voix lorsque les décisions politiques ne tiennent pas compte des données probantes.”
Lisez le commentaire: Des chercheurs canadiens sollicitent de leurs pairs une plus grande présence dans les médias
“The current patchwork of public and private plans across the country means that Canadians are covered for their prescription drugs based on where they live or work, rather than on their medical needs.”
Read the commentary : Quebec’s outdated drug coverage policies should not be a model for the rest of Canada
“When you look at the numbers, it really is surprising that all public employees in Quebec are required to enrol in costly private coverage given that administration costs account for 1.7 percent for Quebec’s public plan, yet 18 percent for private insurers.”
Read the commentary : Quebec’s outdated drug coverage policies should not be a model for the rest of Canada
This free ebook is a compilation of the EvidenceNetwork.ca commentaries published in major newspapers in 2015, written by experts in the health policy field.
